Unable to sell the huge stock of covid vaccine Sputnik Light in the Russia-Ukraine conflict, Bangalore-based Stelis Biopharma has sent a letter to Prime Minister Narendra Modi requesting it to collect jabs for vaccinating citizens or delivering the vaccine to other countries under the alliance. Activities. Stelis Biopharma, the biopharmaceutical arm of Strides Pharma Science, says it has not been able to sell 2.5 million units of the single-dose vaccine it manufactured due to several obstacles following the Russia-Ukraine war.
The Drugs Controller General of India (DCGI) in February this year allowed the emergency use of Sputnik lights subject to certain regulatory provisions. However, at present it is not being operated in the country. In a letter dated May 13, Arun Kumar, founder and director of Stelis Biopharma Ltd, said that after the Prime Minister requested the industry to be prepared for the epidemic, the company had invested more than Rs 700 crore to establish a state-of-the-art vaccine in six months despite COVID-19-induced restrictions. The production facility and the rapid production of Sputnik light began. The company has also received government approval for job production and export.
“We are proud to say that with proper approval from the Government of India, we have started manufacturing Sputnik Light in India and have developed less than 2.5 crore vaccine doses. However, due to a number of restrictions related to Russia, these vaccines are currently unsold to us, “said Kumar. We urge the Government of India to procure our available vaccine and to administer it to the people of India or to donate it to other countries under the India Aid / Covid Friendship Program, “he said.” Sputnik Light is a single dose vaccine and In March 2021, the Russian Direct Investment Fund (RDIF) partnered with Russia’s Sovereign Wealth Fund to develop and supply the Staples vaccine.